Rhythm Vasudeva, Harsh Mehta, Wan-Chi Chan, Sania Jiwani, Sri G Yarlagadda, Prakash Acharya, Prasad Gunasekaran, Georges Hajj, Mark Wiley, Eric Hockstad, Peter Tadros, Kamal Gupta
{"title":"终末期肾脏疾病的稳定性缺血性心脏病经皮冠状动脉介入治疗的全国趋势和结果:一项纵向研究","authors":"Rhythm Vasudeva, Harsh Mehta, Wan-Chi Chan, Sania Jiwani, Sri G Yarlagadda, Prakash Acharya, Prasad Gunasekaran, Georges Hajj, Mark Wiley, Eric Hockstad, Peter Tadros, Kamal Gupta","doi":"10.21037/atm-24-85","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with end-stage kidney disease (ESKD) are at high risk for coronary artery disease. We investigate the trends and outcomes of percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) in patients with ESKD.</p><p><strong>Methods: </strong>We utilized the United States Renal Data System [2010-2018] to include adult patients with ESKD on dialysis for at least 3 months who underwent PCI for SIHD. Patients with myocardial infarction during index hospitalization, history of coronary artery bypass graft or renal transplantation and without Medicare AB coverage were excluded. Trends and related outcomes, including mortality and revascularization rate, were studied.</p><p><strong>Results: </strong>The mean age was 65.1 years with 57.5% male and a majority White (64.5%). The dialysis duration was ≤5 years in 83.3% patients. Hypertension (97.6%) and diabetes mellitus (76.8%) were the most common comorbidities. PCI procedures per 1,000 ESKD patients dropped from 6.2 in 2010 to 2.6 in 2018 (P<0.001) while the index hospitalization mortality increased from 0.9% to 3.0% (P<0.001). The 30-day and 1-year mortality also significantly increased from 3.2% to 6.1% and 26.5% to 31.9%, respectively. However, 1-year repeat revascularization rates dropped from 19.8% to 17.0% between 2010-2018 (P<0.001). A significant increase in comorbidity burden was also noted.</p><p><strong>Conclusions: </strong>We demonstrate a consistent decrease in PCI rates for SIHD in ESKD patients. However, the in-hospital mortality has increased significantly, in part, due to an increasing high-risk profile of these patients. Our results call for individualized clinical decision-making when exploring revascularization options in ESRD patients with SIHD.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 6","pages":"111"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729801/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nationwide trends and outcomes of percutaneous coronary intervention for stable ischemic heart disease in end-stage kidney disease: a longitudinal study.\",\"authors\":\"Rhythm Vasudeva, Harsh Mehta, Wan-Chi Chan, Sania Jiwani, Sri G Yarlagadda, Prakash Acharya, Prasad Gunasekaran, Georges Hajj, Mark Wiley, Eric Hockstad, Peter Tadros, Kamal Gupta\",\"doi\":\"10.21037/atm-24-85\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Patients with end-stage kidney disease (ESKD) are at high risk for coronary artery disease. We investigate the trends and outcomes of percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) in patients with ESKD.</p><p><strong>Methods: </strong>We utilized the United States Renal Data System [2010-2018] to include adult patients with ESKD on dialysis for at least 3 months who underwent PCI for SIHD. Patients with myocardial infarction during index hospitalization, history of coronary artery bypass graft or renal transplantation and without Medicare AB coverage were excluded. Trends and related outcomes, including mortality and revascularization rate, were studied.</p><p><strong>Results: </strong>The mean age was 65.1 years with 57.5% male and a majority White (64.5%). The dialysis duration was ≤5 years in 83.3% patients. Hypertension (97.6%) and diabetes mellitus (76.8%) were the most common comorbidities. PCI procedures per 1,000 ESKD patients dropped from 6.2 in 2010 to 2.6 in 2018 (P<0.001) while the index hospitalization mortality increased from 0.9% to 3.0% (P<0.001). The 30-day and 1-year mortality also significantly increased from 3.2% to 6.1% and 26.5% to 31.9%, respectively. However, 1-year repeat revascularization rates dropped from 19.8% to 17.0% between 2010-2018 (P<0.001). A significant increase in comorbidity burden was also noted.</p><p><strong>Conclusions: </strong>We demonstrate a consistent decrease in PCI rates for SIHD in ESKD patients. However, the in-hospital mortality has increased significantly, in part, due to an increasing high-risk profile of these patients. Our results call for individualized clinical decision-making when exploring revascularization options in ESRD patients with SIHD.</p>\",\"PeriodicalId\":8216,\"journal\":{\"name\":\"Annals of translational medicine\",\"volume\":\"12 6\",\"pages\":\"111\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729801/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of translational medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/atm-24-85\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of translational medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/atm-24-85","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Nationwide trends and outcomes of percutaneous coronary intervention for stable ischemic heart disease in end-stage kidney disease: a longitudinal study.
Background: Patients with end-stage kidney disease (ESKD) are at high risk for coronary artery disease. We investigate the trends and outcomes of percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) in patients with ESKD.
Methods: We utilized the United States Renal Data System [2010-2018] to include adult patients with ESKD on dialysis for at least 3 months who underwent PCI for SIHD. Patients with myocardial infarction during index hospitalization, history of coronary artery bypass graft or renal transplantation and without Medicare AB coverage were excluded. Trends and related outcomes, including mortality and revascularization rate, were studied.
Results: The mean age was 65.1 years with 57.5% male and a majority White (64.5%). The dialysis duration was ≤5 years in 83.3% patients. Hypertension (97.6%) and diabetes mellitus (76.8%) were the most common comorbidities. PCI procedures per 1,000 ESKD patients dropped from 6.2 in 2010 to 2.6 in 2018 (P<0.001) while the index hospitalization mortality increased from 0.9% to 3.0% (P<0.001). The 30-day and 1-year mortality also significantly increased from 3.2% to 6.1% and 26.5% to 31.9%, respectively. However, 1-year repeat revascularization rates dropped from 19.8% to 17.0% between 2010-2018 (P<0.001). A significant increase in comorbidity burden was also noted.
Conclusions: We demonstrate a consistent decrease in PCI rates for SIHD in ESKD patients. However, the in-hospital mortality has increased significantly, in part, due to an increasing high-risk profile of these patients. Our results call for individualized clinical decision-making when exploring revascularization options in ESRD patients with SIHD.
期刊介绍:
The Annals of Translational Medicine (Ann Transl Med; ATM; Print ISSN 2305-5839; Online ISSN 2305-5847) is an international, peer-reviewed Open Access journal featuring original and observational investigations in the broad fields of laboratory, clinical, and public health research, aiming to provide practical up-to-date information in significant research from all subspecialties of medicine and to broaden the readers’ vision and horizon from bench to bed and bed to bench. It is published quarterly (April 2013- Dec. 2013), monthly (Jan. 2014 - Feb. 2015), biweekly (March 2015-) and openly distributed worldwide. Annals of Translational Medicine is indexed in PubMed in Sept 2014 and in SCIE in 2018. Specific areas of interest include, but not limited to, multimodality therapy, epidemiology, biomarkers, imaging, biology, pathology, and technical advances related to medicine. Submissions describing preclinical research with potential for application to human disease, and studies describing research obtained from preliminary human experimentation with potential to further the understanding of biological mechanism underlying disease are encouraged. Also warmly welcome are studies describing public health research pertinent to clinic, disease diagnosis and prevention, or healthcare policy. With a focus on interdisciplinary academic cooperation, ATM aims to expedite the translation of scientific discovery into new or improved standards of management and health outcomes practice.